Announcements Trials
Browse Landscape

Phase

Phase 3 8Phase 2 3Phase NA 2Phase 4 2Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Classical hematology 1

Conditions

Venous Thrombosis 1Venous Thromboembolism 1Pulmonary Embolism 1Lung Neoplasms 1

Interventions

fludarabine phosphate 12Whole-Body Irradiation 11Peripheral Blood Stem Cell Transplantation 11Cyclophosphamide 11Mycophenolic Acid 9fludarabine 7Cyclosporine 6Busulfan 6Tacrolimus 4Melphalan 4Filgrastim 4Cytarabine 4Cord Blood Stem Cell Transplantation 4Antilymphocyte Serum 4eltrombopag 3Flow Cytometry 3Cytogenetic Analysis 3Cyclosporins 3Alemtuzumab 3AP 1903 reagent 3romiplostim 2Transplantation 2Topotecan 2Thiotepa 2Sirolimus 2SRA737 2Radiotherapy 2Gene Expression Profiling 2Etoposide 2Decitabine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Dalteparin × Classical hematology × Clear all
NCT02334007 2018-09-18

Extended Low-Molecular Weight Heparin VTE Prophylaxis in Thoracic Surgery

McMaster University

Phase 1/2 Completed
102 enrolled
Classical hematologyThoracic

Lung Neoplasms, Pulmonary Embolism, Venous Thrombosis, Venous Thromboembolism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡